Axcella Health Inc. operates as a clinical stage biotechnology company in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.75|
|52 Week High||US$2.75|
|52 Week Low||US$6.84|
|1 Month Change||-10.42%|
|3 Month Change||-20.52%|
|1 Year Change||-38.20%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-80.07%|
Recent News & Updates
|AXLA||US Biotechs||US Market|
Return vs Industry: AXLA underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: AXLA underperformed the US Market which returned 30.3% over the past year.
Stable Share Price: AXLA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AXLA's weekly volatility (7%) has been stable over the past year.
About the Company
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company’s lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis.
Axcella Health Fundamentals Summary
|AXLA fundamental statistics|
Is AXLA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AXLA income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.54|
|Net Profit Margin||0.00%|
How did AXLA perform over the long term?See historical performance and comparison
Is Axcella Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AXLA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AXLA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AXLA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AXLA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AXLA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AXLA is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (2.9x).
How is Axcella Health forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AXLA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AXLA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AXLA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AXLA is forecast to have no revenue next year.
High Growth Revenue: AXLA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AXLA is forecast to be unprofitable in 3 years.
How has Axcella Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AXLA is currently unprofitable.
Growing Profit Margin: AXLA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AXLA is unprofitable, and losses have increased over the past 5 years at a rate of 17.3% per year.
Accelerating Growth: Unable to compare AXLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AXLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: AXLA has a negative Return on Equity (-122.17%), as it is currently unprofitable.
How is Axcella Health's financial position?
Financial Position Analysis
Short Term Liabilities: AXLA's short term assets ($80.3M) exceed its short term liabilities ($12.0M).
Long Term Liabilities: AXLA's short term assets ($80.3M) exceed its long term liabilities ($21.4M).
Debt to Equity History and Analysis
Debt Level: AXLA's debt to equity ratio (52.8%) is considered high.
Reducing Debt: Insufficient data to determine if AXLA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AXLA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AXLA has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 16.5% each year.
What is Axcella Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AXLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AXLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AXLA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AXLA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AXLA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bill Hinshaw (52 yo)
Mr. William R. Hinshaw, Jr, also known as Bill, has been President, Chief Executive Officer and Director of Axcella Health Inc. since June 2018. Prior to this role, Mr. Hinshaw held a number of leadership...
CEO Compensation Analysis
Compensation vs Market: Bill's total compensation ($USD1.93M) is above average for companies of similar size in the US market ($USD542.68K).
Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.
Experienced Management: AXLA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: AXLA's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.
Axcella Health Inc.'s employee growth, exchange listings and data sources
- Name: Axcella Health Inc.
- Ticker: AXLA
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$104.989m
- Shares outstanding: 38.18m
- Website: https://www.axcellahealth.com
Number of Employees
- Axcella Health Inc.
- 840 Memorial Drive
- 3rd Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/24 22:05|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.